GT201200023A - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents

Polipéptidos del factor ix modificados y usos de los mismos

Info

Publication number
GT201200023A
GT201200023A GT201200023A GT201200023A GT201200023A GT 201200023 A GT201200023 A GT 201200023A GT 201200023 A GT201200023 A GT 201200023A GT 201200023 A GT201200023 A GT 201200023A GT 201200023 A GT201200023 A GT 201200023A
Authority
GT
Guatemala
Prior art keywords
polipeptides
factor
same
modified factor
modified
Prior art date
Application number
GT201200023A
Other languages
English (en)
Spanish (es)
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wang Jun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200023(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200023A publication Critical patent/GT201200023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GT201200023A 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos GT201200023A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
GT201200023A true GT201200023A (es) 2014-01-27

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200023A GT201200023A (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (enExample)
EP (1) EP2461821A4 (enExample)
JP (1) JP2013500726A (enExample)
KR (1) KR20120060209A (enExample)
CN (1) CN102573890A (enExample)
AU (1) AU2010278721A1 (enExample)
BR (1) BR112012002072A2 (enExample)
CA (1) CA2769258A1 (enExample)
CL (1) CL2012000238A1 (enExample)
CR (1) CR20120052A (enExample)
CU (3) CU20120018A7 (enExample)
DO (1) DOP2012000030A (enExample)
EA (1) EA201290069A1 (enExample)
EC (1) ECSP12011637A (enExample)
GT (1) GT201200023A (enExample)
IN (1) IN2012DN00908A (enExample)
MX (1) MX2012001346A (enExample)
PE (1) PE20121643A1 (enExample)
SG (1) SG178119A1 (enExample)
WO (1) WO2011014890A1 (enExample)
ZA (1) ZA201200716B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
SI3581650T1 (sl) 2008-09-15 2023-06-30 uniQuore biopharma B.V. Polipeptidni mutant faktorja IX, njegova uporaba in metoda za njegovo proizvodnjo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
EP2459224B1 (en) 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
WO2012016131A1 (en) * 2010-07-30 2012-02-02 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
DK2794665T3 (da) * 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
ES2744903T3 (es) * 2012-11-20 2020-02-26 Univ North Carolina Chapel Hill Métodos y composiciones para proteínas del factor IX modificadas
WO2014165189A2 (en) 2013-03-13 2014-10-09 Eli Lilly And Company Modified canine leptin polypeptides
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CN109789181A (zh) 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US12214023B2 (en) 2018-10-18 2025-02-04 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086091A2 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
IN2012DN00908A (enExample) 2015-04-03
EA201290069A1 (ru) 2012-07-30
CN102573890A (zh) 2012-07-11
CL2012000238A1 (es) 2012-10-05
KR20120060209A (ko) 2012-06-11
CU20120018A7 (es) 2012-06-21
US20120164130A1 (en) 2012-06-28
EP2461821A1 (en) 2012-06-13
DOP2012000030A (es) 2012-02-29
CR20120052A (es) 2012-06-04
ZA201200716B (en) 2013-07-31
CU20130057A7 (es) 2013-06-28
BR112012002072A2 (pt) 2016-11-08
WO2011014890A1 (en) 2011-02-03
CU20130058A7 (es) 2013-06-28
AU2010278721A1 (en) 2012-02-16
CA2769258A1 (en) 2011-02-03
SG178119A1 (en) 2012-03-29
ECSP12011637A (es) 2012-02-29
PE20121643A1 (es) 2012-11-25
JP2013500726A (ja) 2013-01-10
MX2012001346A (es) 2012-02-17
EP2461821A4 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
GT201200023A (es) Polipéptidos del factor ix modificados y usos de los mismos
SV2010003704A (es) Polipeptidos modificados del factor ix y usos de los mismos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
HN2012001321A (es) Analogo peptidico de oxintomodulina
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
GT201400164A (es) Compuestos de imidazopirrolidinona
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma